Successful treatment of invasive Rhizopus infection in a child with thalassemia.
The accepted standard for treatment of zygomycetes is amphotericin B and surgical debridement, however recent data suggest that combined treatment modalities may be optimal. Newer anti-fungal agents show success in vitro and in animal models. We present the case of a 10-year-old boy with invasive Rhizopus microsporus var. rhizopodoformis who was successfully treated with a combination of modalities.
Grant
Jennifer M
JM
Montreal Children's Hospital, McGill University Health Centre, Montreal, Canada. Jane.mcdonald@muhc.mcgill.ca
St-Germain
Guy
G
McDonald
Jane C
JC
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D009091:Mucormycosis / Q000188:drug therapy* / Q000382:microbiology / Q000601:surgery*; D012233:Rhizopus / Q000302:isolation & purification; D013789:Thalassemia / Q000150:complications*; D016896:Treatment Outcome
D000935:Antifungal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B